Sanofi restructures US commercial vaccines sales force

Sanofi is over­haul­ing its US com­mer­cial op­er­a­tions for its vac­cines and will cut an undis­closed num­ber of jobs, the com­pa­ny con­firmed to End­points News.

The move fol­lows some big R&D changes in CEO Paul Hud­son’s push to start a new chap­ter at the French phar­ma. Hud­son has set out to in­crease the com­pa­ny’s Phase 3 pipeline by 50% over the next two years and be­come an “im­munol­o­gy pow­er­house.”

While the com­pa­ny re­cent­ly high­light­ed vac­cines as one of its key pri­or­i­ties, a spokesper­son said Thurs­day that it’s “im­ple­ment­ing a stream­lined strate­gic sales struc­ture.” The spokesper­son de­clined to pro­vide fur­ther in­for­ma­tion on the changes that will be made, the time­frame, and the num­ber of em­ploy­ees im­pact­ed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.